EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow Savient to sell, from time to time, up to $200 million of its common stock, debt securities, preferred stock, warrants to purchase common stock, preferred stock or debt securities, or any combination thereof from time to time in one or more offerings. The terms of any offering under the registration statement will be established at the time of the offering and will be described in a prospectus supplement that Savient will file with the SEC.
